Thus, as with SLX4, there might be tissue specificity for the role of MSH2/MSH3 in the cellular response to PARPi, showing sensitization in deficient colon and breast cancer cells, but not in lymphocytes. The gene discussed is SLX4; the disease is breast carcinoma.